Advertisement

General Considerations

  • Mikko SeppänenEmail author
  • Nima Rezaei
Chapter

Abstract

Many genetic and acquired immune-mediated diseases affect the human respiratory system. Currently, there are over 350 Primary Immunodeficiency Dieases (PIDs) known, most of which predispose individuals to airway and lung diseases. We first briefly review different categories of PIDs and why PIDs affect the lungs. We present common features in all PIDs as well as the associated airway infections suggesting the possibility of a PID. The risk of bronchiectasis and various inflammatory disorders of the lungs is increased in PID patients. We give general recommendations into how to diagnose PIDs and the associated lung complications in a patient with compatible features. We also discuss the differential diagnosis between local defects in the lungs and systemic PIDs, as well as the initial assessment and follow-up of lung functions in PID patients. We also emphasize the importance of collaboration between respiratory medicine specialists and clinical PID specialists.

(For further information you may see Rezaei N, Bonilla FA, Seppänen M, de Vries E, Bousfiha AA, Puck J. Introduction on primary immunodeficiency diseases. In: Rezaei N, Aghamohammadi A, Notarangelo LD, editors. Primary immunodeficiency diseases: definition, diagnosis, and management. 2nd ed. p. 1–82.)

Keywords

Immune system diseases Immunologic deficiency syndromes, Immunoproliferative disorders Opportunistic infections Respiratory tract infections Bronchiectasis Granuloma, Respiratory tract Lung diseases, Interstitial Lung diseases, Fungal Pulmonary alveolar proteinosis Pulmonary fibrosis 

References

  1. 1.
    Armstrong J, Gluck EH, Crapo RO, Jones HA, Hughes JM. Lung tissue volume estimated by simultaneous radiographic and helium dilution methods. Thorax. 1982;37(9):676–9.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Borges I, Sena I, Azevedo P, Andreotti J, Almeida V, Paiva A, et al. Lung as a niche for hematopoietic progenitors. Stem Cell Rev. 2017;13(5):567–74.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Mercer RR, Russell ML, Roggli VL, Crapo JD. Cell number and distribution in human and rat airways. Am J Respir Cell Mol Biol. 1994;10(6):613–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Mason RJ, Dobbs LG. Alveolar epithelium and pulmonary surfactant. Murray and Nadel’s textbook of respiratory medicine. 6th ed. Philadelphia: Elsevier; 2016. p. 134–49. e5.Google Scholar
  5. 5.
    Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJA-O, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Picard C, Gaspar HB, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Kaustio M, Haapaniemi E, Goos H, Hautala T, Park G, Syrjanen J, et al. Damaging heterozygous mutations in NFKB1 lead to diverse immunologic phenotypes. J Allergy Clin Immunol. 2017;140(3):782–96.PubMedCrossRefGoogle Scholar
  8. 8.
    Bousfiha A, Jeddane L, Picard C, Ailal F, Gaspar HB, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.PubMedCrossRefGoogle Scholar
  9. 9.
    Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med. 2014;271(5):434–46.CrossRefGoogle Scholar
  10. 10.
    Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc. 2009;84(1):16–22.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Ludviksson BR, Sigurdardottir ST, Johannsson JH, Haraldsson A, Hardarson TO. Epidemiology of Primary Immunodeficiency in Iceland. J Clin Immunol. 2015;35(1):75–9.PubMedCrossRefGoogle Scholar
  12. 12.
    The U.S. Immunodeficiency Network (USIDNET), a program of the Immune Deficiency Foundation (IDF), is supported by a cooperative agreement, U24AI86837, from the National Institute of Allergy and Infectious Diseases (NIAID). https://usidnet.org/registry-data/.
  13. 13.
    Al-Mousa H, Al-Saud B. Primary immunodeficiency diseases in highly consanguineous populations from Middle East and North Africa: epidemiology, diagnosis, and care. Front Immunol. 2017;8:678.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Immunodeficiencies ESf. Registry Working Party ESID Database Statistics; Update June 19, 2018. 2018. https://esid.org/Working-Parties/Registry-Working-Party/ESID-Database-Statistics.
  15. 15.
    Leiva LE, Zelazco M, Oleastro M, Carneiro-Sampaio M, Condino-Neto A, Costa-Carvalho BT, Grumach AS, et al. Primary immunodeficiency diseases in Latin America: the second report of the LAGID registry. J Clin Immunol. 2007;27(1):101–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Modell V, Quinn J, Orange J, Notarangelo LD, Modell F. Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network. Immunol Res. 2016;64(3):736–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Trotta L, Hautala T, Hamalainen S, Syrjanen J, Viskari H, Almusa H, et al. Enrichment of rare variants in population isolates: single AICDA mutation responsible for hyper-IgM syndrome type 2 in Finland. Eur J Hum Genet. 2016;24(10):1473.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Selenius JS, Martelius T, Pikkarainen S, Siitonen S, Mattila E, Pietikäinen R, et al. Unexpectedly high prevalence of common variable immunodeficiency in Finland. Front Immunol. 2017;8:1190.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Griffith LM, Cowan MJ, Notarangelo LD, Puck JM, Buckley RH, Candotti F, Conley ME, et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol. 2009;124(6):1152–60.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Gennery AR, Holland SM. Primary immunodeficiencies: not just paediatric diseases. Eur Respir J. 2015;45:1521–3.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60.CrossRefGoogle Scholar
  23. 23.
    Netea MG, van der Meer JW. Trained immunity: an ancient way of remembering. Cell Host Microbe. 2017;21(3):297–300.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the twenty-first century. Ann N Y Acad Sci. 2011;1238(1):7–14.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Al-Herz W, Aldhekri H, Barbouche MR, Rezaei N. Consanguinity and primary immunodeficiencies. Hum Hered. 2014;77(1–4):138–43.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Wood P, Network UPI. Primary antibody deficiencies: recognition, clinical diagnosis and referral of patients. Clin Med (Lond). 2009;9(6):595–9.CrossRefGoogle Scholar
  27. 27.
    Arnold DF, Wiggins J, Cunningham-Rundles C, Misbah SA, Chapel HM. Granulomatous disease: distinguishing primary antibody disease from sarcoidosis. Clin Immunol. 2008;128(1):18.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Verbsky JW, Routes JM, editors. Sarcoidosis and common variable immunodeficiency: similarities and differences. Seminars in respiratory and critical care medicine. Stuttgart: Thieme Medical Publishers; 2014.Google Scholar
  29. 29.
    Juhn YJ. Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease? J Allergy Clin Immunol. 2014;134(2):247–57.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Jung JA, Kita H, Yawn BP, Boyce TG, Yoo KH, McGree ME, Weaver AL, et al. Increased risk of serious pneumococcal disease in patients with atopic conditions other than asthma. J Allergy Clin Immunol. 2010;125(1):217–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Griffith LM, Cowan MJ, Notarangelo LD, Kohn DB, Puck JM, Pai S-Y, et al. Primary immune deficiency treatment consortium (PIDTC) report. J Allergy Clin Immunol. 2014;133(2):335–47. e11.PubMedCrossRefGoogle Scholar
  33. 33.
    McAleer MA, Pohler E, Smith FJ, Wilson NJ, Cole C, MacGowan S, et al. Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol. 2015;136(5):1268–76.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Luk ADW, Lee PP, Mao H, Chan K-W, Chen XY, Chen T-X, et al. Family history of early infant Death correlates with earlier age at Diagnosis But not shorter Time to Diagnosis for severe combined immunodeficiency. Front Immunol. 2017;8:808.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Nelson KS, Lewis DB. Adult-onset presentations of genetic immunodeficiencies: genes can throw slow curves. Curr Opin Infect Dis. 2010;23(4):359.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Woroniecka M, Ballow M. Office evaluation of children with recurrent infection. Pediatr Clin N Am. 2000;47(6):1211–24.CrossRefGoogle Scholar
  37. 37.
    Immunology EAoAaC. European position paper on rhinosinusitis and nasal polyps. Rhinol Suppl. 2005;18:1–87.Google Scholar
  38. 38.
    Wood P, Peckham D. Investigating recurrent respiratory infections in primary care. BMJ (CR)-print. 2009;339(2):b4118.PubMedCrossRefGoogle Scholar
  39. 39.
    Gokturk B, Keles S, Kirac M, Artac H, Tokgoz H, Guner S, et al. CD3G gene defects in familial autoimmune thyroiditis. Scand J Immunol. 2014;80(5):354–61.PubMedCrossRefGoogle Scholar
  40. 40.
    von Bernuth H, Picard C, Puel A, Casanova JL. Experimental and natural infections in M y D 88-and IRAK-4-deficient mice and humans. Eur J Immunol. 2012;42(12):3126–35.CrossRefGoogle Scholar
  41. 41.
    Yalçın E, Doğru D, Özçelik U, Kiper N, Aslan AT, Gözaçan A. Tracheomalacia and bronchomalacia in 34 children: clinical and radiologic profiles and associations with other diseases. Clin Pediatr. 2005;44(9):777–81.CrossRefGoogle Scholar
  42. 42.
    Einarsdottir H, Erlendsdottir H, Kristinsson K, Gottfredsson M. Nationwide study of recurrent invasive pneumococcal infections in a population with a low prevalence of human immunodeficiency virus infection. Clin Microbiol Infect. 2005;11(9):744–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Gaschignard J, Levy C, Chrabieh M, Boisson B, Bost-Bru C, Dauger S, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis. 2014;59(2):244–51.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Netea MG, van der Meer JW. Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med. 2011;364(1):60–70.PubMedCrossRefGoogle Scholar
  45. 45.
    Chan ED, Iseman MD. Bronchiectasis. In: Broaddus VC, Ernst JD, Gotway MB, King TE, Lazarus SC, Mason RJ, et al., editors. Murray and Nadel’s textbook of respiratory medicine. 6th ed. Philadelphia: Elsevier - Health Sciences Division; 2016. p. 853–76.Google Scholar
  46. 46.
    Jesenak M, Banovcin P, Jesenakova B, Babusikova E. Pulmonary manifestations of primary immunodeficiency disorders in children. Front Pediatr. 2014;2:77.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Truong T. The overlap of bronchiectasis and immunodeficiency with asthma. Immunol Allergy Clin North Am. 2013;33(1):61–78.PubMedCrossRefGoogle Scholar
  48. 48.
    Yazdani R, Abolhassani H, Asgardoon M, Shaghaghi M, Modaresi M, Azizi G, et al. Infectious and noninfectious pulmonary complications in patients with primary immunodeficiency disorders. J Investig Allergol Clin Immunol. 2017;27(4):213–24.PubMedCrossRefGoogle Scholar
  49. 49.
    McShane PJ, Naureckas ET, Tino G, Strek ME. Non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Agondi R, Barros M, Rizzo L, Kalil J, Giavina-Bianchi P. Allergic asthma in patients with common variable immunodeficiency. Allergy. 2010;65(4):510–5.PubMedCrossRefGoogle Scholar
  51. 51.
    Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129(2):280–91.PubMedCrossRefGoogle Scholar
  52. 52.
    Muldoon EG, Strek ME, Patterson KC. Allergic and noninvasive infectious pulmonary aspergillosis syndromes. Clin Chest Med. 2017;38(3):521–34.PubMedCrossRefGoogle Scholar
  53. 53.
    Denning DW, Chakrabarti A. Pulmonary and sinus fungal diseases in non-immunocompromised patients. Lancet Infect Dis. 2017;17(11):e357–66.PubMedCrossRefGoogle Scholar
  54. 54.
    Owayed A, Al-Herz W. Sinopulmonary complications in subjects with primary immunodeficiency. Respir Care. 2016.  https://doi.org/10.4187/respcare.04479.PubMedCrossRefGoogle Scholar
  55. 55.
    Rezaei N, de Vrie E, Gambineri E, Haddad E. Common presentations and diagnostic approaches. In: Sullivan K, Stiehm ER, editors. Stiehm’s immune deficiencies. 1st ed. Amsterdam: Academic Press; 2014. p. 3–59.CrossRefGoogle Scholar
  56. 56.
    Szymanski EP, Leung JM, Fowler CJ, Haney C, Hsu AP, Chen F, et al. Pulmonary nontuberculous mycobacterial infection. A multisystem, multigenic disease. Am J Respir Crit Care Med. 2015;192(5):618–28.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Aksamit TR, O’donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017;151(5):982–92.PubMedCrossRefGoogle Scholar
  58. 58.
    Nonas S. Pulmonary manifestations of primary immunodeficiency disorders. Immunol Allergy Clin North Am. 2015;35(4):753–66.PubMedCrossRefGoogle Scholar
  59. 59.
    Freeman AF, Olivier KN. Hyper-IgE syndromes and the lung. Clin Chest Med. 2016;37(3):557–67.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Wood P, Stanworth S, Burton J, Jones A, Peckham D, Green T, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149(3):410–23.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–i58.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Schussler E, Beasley MB, Maglione PJ. Lung disease in primary antibody deficiencies. J Allergy Clin Immunol Pract. 2016;4(6):1039–52.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016;4(6):1066–75.PubMedCrossRefGoogle Scholar
  64. 64.
    Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, Blaese RM, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014;133(4):961–6.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Kroger A, Duchin J, Vázquez M. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: US Department of Health and Human Services, CDC; 2017.Google Scholar
  66. 66.
    Bates CA, Ellison MC, Lynch DA, Cool CD, Brown KK, Routes JM. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol. 2004;114(2):415–21.PubMedCrossRefGoogle Scholar
  67. 67.
    Wheat WH, Cool CD, Morimoto Y, Rai PR, Kirkpatrick CH, Lindenbaum BA, et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med. 2005;202(4):479–84.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    van Moorsel CH, ten Klooster L, van Oosterhout MF, de Jong PA, Adams H, Wouter van Es H, et al. SFTPA2 mutations in familial and sporadic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2015;192(10):1249–52.PubMedCrossRefGoogle Scholar
  69. 69.
    Verma N, Grimbacher B, Hurst JR. Lung disease in primary antibody deficiency. Lancet Respir Med. 2015;3(8):651–60.PubMedCrossRefGoogle Scholar
  70. 70.
    Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, et al. British Lung Foundation/United Kingdom primary immunodeficiency network consensus statement on the definition, diagnosis, and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2017;5(4):938–45.PubMedCrossRefGoogle Scholar
  71. 71.
    Becker ML, Martin TM, Doyle TM, Rosé CD. Interstitial pneumonitis in Blau syndrome with documented mutation in CARD15. Arthritis Rheum. 2007;56(4):1292–4.PubMedCrossRefGoogle Scholar
  72. 72.
    Bodemer C, Sauvage V, Mahlaoui N, Cheval J, Couderc T, Leclerc-Mercier S, et al. Live rubella virus vaccine long-term persistence as an antigenic trigger of cutaneous granulomas in patients with primary immunodeficiency. Clin Microbiol Infect. 2014;20(10):O656–O63.PubMedCrossRefGoogle Scholar
  73. 73.
    Perelygina L, Plotkin S, Russo P, Hautala T, Bonilla F, Ochs HD, et al. Rubella persistence in epidermal keratinocytes and granuloma M2 macrophages in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2016;138(5):1436–9. e11.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Gadola S, Moins-Teisserenc H, Trowsdale J, Gross W, Cerundolo V. TAP deficiency syndrome: IMMUNODEFICIENCY REVIEW. Clin Exp Immunol. 2000;121(2):173–8.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Rao N, Mackinnon AC, Routes JM. Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency—histologic and immunohistochemical analyses of 16 cases. Hum Pathol. 2015;46(9):1306–14.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Allenspach E, Torgerson TR. Autoimmunity and primary immunodeficiency disorders. J Clin Immunol. 2016;36(1):57–67.PubMedCrossRefGoogle Scholar
  77. 77.
    Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46(12):3340–8.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Kaufman J, Komorowski R. Bronchiolitis obliterans organizing pneumonia in common variable immunodeficiency syndrome. Chest. 1991;100(2):552–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Shokri S, Nabavi M, Hirschmugl T, Aghamohammadi A, Arshi S, Bemanian MH, et al. LPS-responsive beige-like anchor gene mutation associated with possible Bronchiolitis Obliterans organizing pneumonia associated with Hypogammaglobulinemia and normal IgM phenotype and low number of B cells. Acta Med Iran. 2016;54(10):620–3.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Tamada T, Nara M, Tomaki M, Ashino Y, Hattori T. Secondary bronchiolitis obliterans organising pneumonia in a patient with carbamazepine-induced hypogammaglobulinemia. Thorax. 2007;62(1):100.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Pohl W, Armbruster C, Bernhardt K, Drlicek M, Vetter N. Idiopathic CD4+ T-lymphocytopenia in 2 patients without indications for HIV infection. Wien Klin Wochenschr. 1995;107(3):95–100.PubMedGoogle Scholar
  82. 82.
    Mason RJ, Dobbs LG. Alveolar epithelium and pulmonary surfactant. In: Broaddus VC, Ernst JD, Gotway MB, King TE, Lazarus SC, Mason RJ, et al., editors. Murray and Nadel’s textbook of respiratory medicine. 6th ed; 2016. p. 134–49.CrossRefGoogle Scholar
  83. 83.
    Haapaniemi EM, Kaustio M, Rajala HL, van Adrichem AJ, Kainulainen L, Glumoff V, et al. Autoimmunity, hypogammaglobulinemia, lymphoproliferation and mycobacterial disease in patients with dominant activating mutations in STAT3. Blood. 2014.  https://doi.org/10.1182/blood-2014-04-570101.PubMedCrossRefGoogle Scholar
  84. 84.
    Snetselaar R, Van Moorsel CH, Kazemier KM, Van Der Vis JJ, Zanen P, Van Oosterhout MF, et al. Telomere length in interstitial lung diseases. Chest. 2015;148(4):1011–8.PubMedCrossRefGoogle Scholar
  85. 85.
    Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48(6):1710–20.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Ballew BJ, Savage SA. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013;6(3):327–37.PubMedCrossRefGoogle Scholar
  87. 87.
    Speckmann C, Sahoo SS, Rizzi M, Hirabayashi S, Karow A, Serwas NK, et al. Clinical and molecular heterogeneity of RTEL1 deficiency. Front Immunol. 2017;8:449.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Petrovski S, Todd JL, Durheim MT, Wang Q, Chien JW, Kelly FL, et al. An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(1):82–93.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Stella GM, Balestro E, Lacedonia D, Baraldo S. Telomeropathies: an emerging spectrum of disorders with important implications for patients with interstitial lung disease. Minerva Med. 2016;107(1 Suppl 1):9–14.PubMedGoogle Scholar
  90. 90.
    Haycock PC, Burgess S, Nounu A, Zheng J, Okoli GN, Bowden J, et al. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol. 2017;3(5):636–51.PubMedCrossRefGoogle Scholar
  91. 91.
    Bhatt JM, Bush A, van Gerven M, Nissenkorn A, Renke M, Yarlett L, et al. Ataxia telangiectasia: why should the ERS care? Eur Respir J. 2015;46(6):1557–60.PubMedCrossRefGoogle Scholar
  92. 92.
    Vicary GW, Vergne Y, Santiago-Cornier A, Young LR, Roman J. Pulmonary fibrosis in Hermansky–Pudlak syndrome. Ann Am Thorac Soc. 2016;13(10):1839–46.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Somech R, Somers GR, Chitayat D, Grunebaum E, Atkinson A, Kolomietz E, et al. Fatal lung fibrosis associated with immunodeficiency and gonadal dysgenesis in 46XX sisters—a new syndrome. Am J Med Genet A. 2008;146(1):8–14.CrossRefGoogle Scholar
  94. 94.
    Ballerie A, Nimubona S, Meunier C, Gutierrez FL, Desrues B, Delaval P, et al. Association of pulmonary alveolar proteinosis and fibrosis: patient with GATA2 deficiency. Eur Respir J. 2016.  https://doi.org/10.1183/13993003.00252-2016.PubMedCrossRefGoogle Scholar
  95. 95.
    Siddiqui S, Anderson VL, Hilligoss DM, Abinun M, Kuijpers TW, Masur H, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45(6):673–81.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Lohr NJ, Molleston JP, Strauss KA, Torres-Martinez W, Sherman EA, Squires RH, et al. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am J Hum Genet. 2010;86(3):447–53.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Trapnell BC, Luisetti M. Pulmonary alveolar proteinosis syndrome. In: Broaddus VC, Ernst JD, Gotway MB, King TE, Lazarus SC, Mason RJ, et al., editors. Nadel’s textbook of respiratory medicine. 6th ed; 2015. p. 1260–74.Google Scholar
  98. 98.
    Ito M, Nakagome K, Ohta H, Akasaka K, Uchida Y, Hashimoto A, et al. Elderly-onset hereditary pulmonary alveolar proteinosis and its cytokine profile. BMC pulmonary medicine. 2017;17(1):40.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Hsu AP, McReynolds LJ, Holland SM. GATA2 deficiency. Curr Opin Allergy Clin Immunol. 2015;15(1):104.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Imielinski M, Guo G, Meyerson M. Insertions and deletions target lineage-defining genes in human cancers. Cell. 2017;168(3):460–72. e14.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Mayor PC, Eng KH, Singel KL, Abrams SI, Odunsi K, Moysich KB, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States immune deficiency network registry. J Allergy Clin Immunol. 2018;141(3):1028–35.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Mortaz E, Tabarsi P, Mansouri D, Khosravi A, Garssen J, Velayati A, et al. Cancers related to immunodeficiencies: update and perspectives. Front Immunol. 2016;7:365.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Hauck F, Voss R, Urban C, Seidel MG. Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. J Allergy Clin Immunol. 2018;141(1):59–68. e4.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Milito C, Pulvirenti F, Serra G, Valente M, Pesce AM, Granata G, et al. Lung magnetic resonance imaging with diffusion weighted imaging provides regional structural as well as functional information without radiation exposure in primary antibody deficiencies. J Clin Immunol. 2015;35(5):491–500.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Serra G, Milito C, Mitrevski M, Granata G, Martini H, Pesce AM, et al. Lung MRI as a possible alternative to CT scan for patients with primary immune deficiencies and increased radiosensitivity. Chest. 2011;140(6):1581–9.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, et al. Non-Hodgkin’s lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica. 2016.  https://doi.org/10.3324/haematol.2016.147116.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Vece TJ, Watkin LB, Nicholas SK, Canter D, Braun MC, Guillerman RP, et al. Copa syndrome: a novel autosomal dominant immune dysregulatory disease. J Clin Immunol. 2016;36(4):377–87.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Johnston S, Hill S, Lock R, Dwight J, Unsworth D, Gompels M. Echocardiographic abnormalities in primary antibody deficiency. Postgrad Med J. 2004;80(942):214–8.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, et al. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2013.  https://doi.org/10.1182/blood-2013-07-515528.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Rossoff LJ, Genovese J, Coleman M, Dantzker DR. Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy. Chest. 1997;112(2):551–3.PubMedCrossRefGoogle Scholar
  111. 111.
    Grossi O, Horeau-Langlard D, Agard C, Haloun A, Lefebvre M, Neel A, et al. Low-dose methotrexate in PAH related to T-cell large granular lymphocyte leukaemia. Eur Respir J. 2012;39(2):493–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Jouneau S, Ballerie A. Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. Eur Respir J. 2017;49(5).PubMedCrossRefGoogle Scholar
  113. 113.
    Sanges S, Prévotat A, Fertin M, Terriou L, Lefèvre G, Quesnel B, et al. Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis. Eur Respir J. 2017;49(5):1700178.PubMedCrossRefGoogle Scholar
  114. 114.
    Niemela J, Kuehn HS, Kelly C, Zhang M, Davies J, Melendez J, et al. Caspase-8 deficiency presenting as late-onset multi-organ lymphocytic infiltration with granulomas in two adult siblings. J Clin Immunol. 2015;35(4):348–55.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Griese M, Zarbock R, Costabel U, Hildebrandt J, Theegarten D, Albert M, et al. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulm Med. 2015;15(1):87.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Jouhadi Z, Khadir K, Ailal F, Bouayad K, Nadifi S, Engelhardt KR, et al. Ten-year follow-up of a DOCK8-deficient child with features of systemic lupus erythematosus. Pediatrics. 2014.  https://doi.org/10.1542/peds.2013-1383.PubMedCrossRefGoogle Scholar
  117. 117.
    Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, et al. Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 2016;138(4):957–69.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Ho SW, Teng YH, Yang SF, Yeh HW, Wang YH, Chou MC, et al. Association of proton pump inhibitors usage with risk of pneumonia in dementia patients. J Am Geriatr Soc. 2017;65(7):1441–7.PubMedCrossRefGoogle Scholar
  119. 119.
    Gelfand EW, Ochs HD, Shearer WT. Controversies in IgG replacement therapy in patients with antibody deficiency diseases. J Allergy Clin Immunol. 2013;131(4):1001–5.PubMedCrossRefGoogle Scholar
  120. 120.
    Kishiyama J, Valacer D, Cunningham-Rundles C, Sperber K, Richmond G, Abramson S, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol. 1999;91(2):126–33.PubMedCrossRefGoogle Scholar
  121. 121.
    Borgers H, Jeurissen A, Flamaing J, Peetermans W, Moens L, Verhaegen J, et al. Elderly subjects do not show impaired pneumococcal capsular polysaccharide serotype-specific antibody responses as assessed by a multiplexed bead assay. Clin Immunol. 2010;135(3):501–2.PubMedCrossRefGoogle Scholar
  122. 122.
    Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol. 2010;134(2):198–205.PubMedCrossRefGoogle Scholar
  123. 123.
    Cunningham-Rundles C. Key aspects for successful immunoglobulin therapy of primary immunodeficiencies. Clin Exp Immunol. 2011;164:16–9.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Wirsum C, Glaser C, Gutenberger S, Keller B, Unger S, Voll RE, et al. Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency. J Clin Immunol. 2016;36(4):406–12.PubMedCrossRefGoogle Scholar
  125. 125.
    Beck SC. Making sense of serotype-specific pneumococcal antibody measurements. London, England: SAGE Publications Sage UK; 2013.CrossRefGoogle Scholar
  126. 126.
    Schaballie H, Bosch B, Schrijvers R, Proesmans M, De Boeck K, Boon MN, et al. Fifth percentile cutoff values for antipneumococcal polysaccharide and anti-Salmonella typhi Vi IgG describe a normal polysaccharide response. Front Immunol. 2017;8:546.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Jolles S, Sánchez-Ramón S, Quinti I, Soler-Palacín P, Agostini C, Florkin B, et al. Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. Clin Exp Immunol. 2017;190(2):226–34.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Komarow HD, Sokolic R, Hershfield MS, Kohn DB, Young M, Metcalfe DD, et al. Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. Orphanet J Rare Dis. 2015;10(1):159.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Sullivan KE, Bassiri H, Bousfiha AA, Costa-Carvalho BT, Freeman AF, Hagin D, et al. Erratum to: emerging infections and pertinent infections related to travel for patients with primary immunodeficiencies. J Clin Immunol. 2017;37(7):693.PubMedCrossRefGoogle Scholar
  130. 130.
    Heimall J, Buckley RH, Puck J, Fleisher TA, Gennery AR, Haddad E, et al. Recommendations for screening and management of late effects in patients with severe combined immunodeficiency after allogenic hematopoietic cell transplantation: a consensus statement from the second Pediatric Blood and Marrow Transplant Consortium international conference on late effects after pediatric HCT. Biol Blood Marrow Transplant. 2017;23(8):1229–40.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Rare Disease Center, New Children’s HospitalUniversity of Helsinki and Helsinki University HospitalHelsinkiFinland
  2. 2.Adult Primary Immunodeficiency Clinic, Inflammation CenterUniversity of Helsinki and Helsinki University HospitalHelsinkiFinland
  3. 3.Research Center for Immunodeficiencies, Children’s Medical Center, Tehran University of Medical SciencesTehranIran
  4. 4.Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN)TehranIran
  5. 5.Department of Immunology, School of MedicineTehran University of Medical SciencesTehranIran

Personalised recommendations